The results of the SEARCH-AF trial (NCT02793895) were presented by Prof. Subodh Verma (St. Michael's Hospital; University of Toronto, Canada). He explained that POAF occurs post-operatively in 30â50% of patients, peaking at 3â5 days; whether the risk of POAF persists thereafter is unknown. The SEARCH-AF trial set out to test whether enhanced cardiac rhythm monitoring after cardiac surgery would improve AF detection in high-risk patients. The participants were post-cardiac surgical patients (with isolated coronary artery bypass grafting [CABG] or valve replacement/repair ± CABG) with CHA2DS2-VASc â„4 or â„2 with additional risk factors for POAF who did not have a history of pre-operative AF. Participants were randomised 1:1 to 30 days of post-discharge continuous cardiac rhythm monitoring with an adhesive monitoring device or usual care. The primary endpoint was cumulative documented AF or atrial flutter lasting â„6 minutes within 30 days of randomisation.
The analysis was based on results from the 336 patients (85% of the planned sample size) who were randomised before enrolment was suspended due to COVID-19. Mean age was 67±9 years, mean CHA2DS2-VASc was 3.7±1.1, and median follow-up was 9 months. The primary outcome occurred in 32 (19.6%) patients of the monitoring group and 3 (1.7%) in the control group. This corresponds to an absolute risk difference of 17.9% (95% CI 11.5â24.3%; P<0.001). The number needed to screen was 6 (95% CI 4â9). AF or atrial flutter lasting â„6 hours was detected in 8.6% of the monitoring group and 0% of the control group (P<0.001). The rates of oral anticoagulation were lower than the rates of detected AF.
Prof. Verma concluded that POAF after cardiac surgery is not confined to the hospitalisation period. These data should help inform clinical practice guidelines on monitoring for POAF in such patients.
- Verma S, et al. Enhanced Monitoring for Atrial Fibrillation Following Cardiac Surgery: Primary Results of the SEARCH-AF Cardiolink Randomized Trial. LBS.06, AHA Scientific Sessions 2020, 13â17 Nov.
Posted on
Previous Article
« Extra imaging reveals cause of MINOCA in women Next Article
Ticagrelor/aspirin reduces stroke risk in patients with ipsilateral cervicocranial plaque »
« Extra imaging reveals cause of MINOCA in women Next Article
Ticagrelor/aspirin reduces stroke risk in patients with ipsilateral cervicocranial plaque »
Table of Contents: AHA 2020
Featured articles
COVID-19 and Influenza
Fewer CV complications than expected in AHA COVID-19 Registry
Worse COVID-19 outcomes in younger obese patients
Effects of CVD in hospitalised COVID-19 patients
Unfavourable outcomes for COVID-19 patients with AF and atrial flutter
High-dose influenza vaccine in patients with CVD
Atrial Fibrillation
Vitamin D or omega 3 fatty acids do not prevent AF
Active screening for AF improves clinical outcomes
AF screening in older adults at primary care visits
CVD Risk Reduction
Clever trial design gets patients back on statins: the SAMSON trial
Polypill plus aspirin reduces cardiovascular events
Lowering LDL cholesterol in older patients is beneficial
No CV benefit from omega 3 in high-risk patients
Safety and efficacy of inclisiran for hypercholesterolemia
Remote risk management programme effective and efficient
Healthy lifestyle lowers mortality irrespective of medication burden
Heart Failure
Omecamtiv mecarbil improves outcomes in HFrEF-patients
IV iron reduces HF hospitalisation
Dapagliflozin reduces renal risk independent of CV disease status
âStrongly consider an SGLT2-inhibitor in most T2DM patientsâ
Additional HFrEF education and patient-engagement tools
Acute Coronary Syndrome
No benefit from omega-3 fatty acids after recent MI
PIONEER III trial: Drug-eluting stents comparable
Coronary and Valve Disease
Extra imaging reveals cause of MINOCA in women
Ticagrelor not superior to clopidogrel after elective PCI
Stroke
Ticagrelor/aspirin reduces stroke risk in patients with ipsilateral cervicocranial plaque
AF monitoring following cardiovascular surgery
Miscellaneous
PAD: Rivaroxaban reduces VTE risk after revascularisation
Sotatercept: potential new treatment option for PAH
Finerenone lowers CV events in diabetic CKD patients
Mavacamten effective in obstructive hypertrophic cardiomyopathy
Children exposed to tobacco smoke have worse heart function as adults
Transgender people have unaddressed heart disease risks
Intensive blood pressure lowering benefits older adults
Longer chest compression pause worsens outcomes after paediatric IHCA
Related Articles

February 17, 2021
Unfavourable outcomes for COVID-19 patients with AF and atrial flutter
February 17, 2021
Vitamin D or omega 3 fatty acids do not prevent AF

February 18, 2021
Rilonacept reduces risk of pericarditis recurrence
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com